BIND Therapeutics, Inc. (NASDAQ:BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands. BIND Therapeutics Inc. (NASDAQ:BIND) weekly performance is 2.80%. On last trading day company shares ended up $10.66. Analysts mean target price for the company is $23.67. BIND Therapeutics Inc. (NASDAQ:BIND) distance from 50-day simple moving average (SMA50) is 14.45%.
Applied Genetic Technologies Corp (NASDAQ:AGTC)’s Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in New York. Ms. Washer will participate in panel discussions entitled “Ophthalmology: Seeing the Future of Gene Therapy Clearly” Applied Genetic Technologies Corp (NASDAQ:AGTC) shares fell -2.34% in last trading session and ended the day on $30.95. AGTC return on assets is -60.40%.
Genocea Biosciences Inc. (NASDAQ:GNCA) announced on 9 may, Grant revenue was $0 and $259 thousand for the three months ended March 31, 2014 and 2013, respectively. The decrease of $0.3 million was due to the completion of a grant to fund research for our pneumococcus program during 2013. Genocea Biosciences Inc. (NASDAQ:GNCA) shares moved up 10.48% in last trading session and was closed at $20.88, while trading in range of $18.74 – $21.36. Genocea Biosciences Inc. (NASDAQ:GNCA) year to date (YTD) performance is 89.82%.
Insmed Incorporated (NASDAQ:INSM) shares skyrocketed 42.6% after it received breakthrough therapy designation for Arikayce from the FDA. The designation was granted to Arikayce for curing patients suffering from treatment resistant nontuberculous mycobacterial (NTM) lung infections. Insmed Incorporated (NASDAQ:INSM) ended the last trading day at $18.80. Company weekly volatility is calculated as 7.99% and price to cash ratio as 7.29.Insmed Incorporated (NASDAQ:INSM) showed a positive weekly performance of 49.80%.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) announced on 15 may, Revenues were $0.6 million during the quarter ended March 31, 2014 compared to $0 for the quarter ended March 31, 2013 and include amounts from the Thrombogenics collaboration which began in May 2013. Eleven Biotherapeutics Inc. (NASDAQ:EBIO) weekly performance is 5.20%. On last trading day company shares ended up $12.34. Analysts mean target price for the company is $28.00. Eleven Biotherapeutics Inc. (NASDAQ:EBIO) distance from 50-day simple moving average (SMA50) is 2.15%.